Prosecution Insights
Last updated: November 15, 2026

Caribou Biosciences Inc.

Technology area: Biotechnology & Pharmaceuticals

4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Analysis

Caribou Biosciences Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 examiners and 4 art units, indicating that each pending matter follows a separate examination path.

DAUNER, JOSEPH G is the busiest examiner, with 1 pending matter. The evenly distributed examiner assignments make centralized docket management and consistent portfolio positions especially useful.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

4
Total Pending OAs
2
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (50%)
1
Medium (25%)
1
Easy (25%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (25%)
Double-patenting + other1 (25%)
Multi-statute (no §101)2 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
DAUNER, JOSEPH G 1 56.8% +35.6%
DUFFY, BRADLEY 1 54.5% +46.0%
KONOPKA, CATHERINE ANNE 1 57.2% +66.3%
PYLA, EVELYN Y 1 55.8% +47.1%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
17725324 CRISPR ABASIC RESTRICTED NUCLEOTIDES AND CRISPR ACCURACY VIA ANALOGS PYLA, EVELYN Y 15d
18704687 EXONUCLEASE-COUPLED REAL-TIME ENDONUCLEASE ACTIVITY ASSAY DAUNER, JOSEPH G —

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18390978 TREATMENT OF AUTOIMMUNE DISEASES WITH ENGINEERED IMMUNE CELLS DUFFY, BRADLEY 45d overdue
17725324 CRISPR ABASIC RESTRICTED NUCLEOTIDES AND CRISPR ACCURACY VIA ANALOGS PYLA, EVELYN Y 15d
18704687 EXONUCLEASE-COUPLED REAL-TIME ENDONUCLEASE ACTIVITY ASSAY DAUNER, JOSEPH G —
18320355 COMPOSITIONS AND METHODS OF NUCLEIC ACID-TARGETING NUCLEIC ACIDS KONOPKA, CATHERINE ANNE —

Top Art Units

Art UnitApps
1682 1
1643 1
1635 1
1633 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18704687 EXONUCLEASE-COUPLED REAL-TIME ENDONUCLEASE ACTIVITY ASSAY DAUNER, JOSEPH G 1682 §102§103§112 Non-Final OA — Pending Apr 25, 2024
18390978 TREATMENT OF AUTOIMMUNE DISEASES WITH ENGINEERED IMMUNE CELLS DUFFY, BRADLEY 1643 §103DP Final Rejection 45d overdue Pending Dec 20, 2023
18320355 COMPOSITIONS AND METHODS OF NUCLEIC ACID-TARGETING NUCLEIC ACIDS KONOPKA, CATHERINE ANNE 1635 §112Other Final Rejection — Pending May 19, 2023
17725324 CRISPR ABASIC RESTRICTED NUCLEOTIDES AND CRISPR ACCURACY VIA ANALOGS PYLA, EVELYN Y 1633 §102§103 Non-Final OA 15d Pending Apr 20, 2022

Managing Caribou Biosciences Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Caribou Biosciences Inc. have?

Caribou Biosciences Inc. has 4 pending office actions as of November 2026, spread across 4 art units and 4 examiners.

Which USPTO examiner handles the most Caribou Biosciences Inc. applications?

Joseph G Dauner has the most, with 1 of Caribou Biosciences Inc.'s pending office actions.

What technology area are Caribou Biosciences Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month